ライフサイエンスコーパス: be complete

1 o not proceed to selection before evaluation is complete.

2 ess can be induced after retinal development is complete.

3 ered at ClinicalTrials.gov, NCT02453308, and is complete.

4 rial Registry, ISRCTN43811467, and enrolment is complete.

5 is typically downregulated after development is complete.

6 d Trial registry, number ISRCTN43958015, and is complete.

7 ding and then turn over rapidly when folding is complete.

8 The study is ongoing and recruitment is complete.

9 e G1/S transition after the origin licensing is complete.

10 a signal is received that divisome assembly is complete.

11 fter migration to and dispersion within dLGN is complete.

12 struction begins before chromosome alignment is complete.

13 s of alkyl halides formed after the reaction is complete.

14 ogous hosts has confirmed that most pathways are complete.

15 red with ClinicalTrials.gov, NCT02848326 and is completed.

16 red with ClinicalTrials.gov, NCT01895777 and is completed.

17 inicalTrials.gov, NCT02924376, and enrolment is completed.

18 and all research related to Lung-MAP (S1400) is completed.

19 defer DAA therapy until after HCC treatment is completed.

20 ISRCTN registry, number ISRCTN41083256, and is completed.

21 ered with ISRCTN, number ISRCTN22888906, and is completed.

22 ield stage and decreasing once morphogenesis is completed.

23 ith the ISRCTN registry, ISRCTN68382401, and is completed.

24 registered with ISRCTN, ISRCTN92746680, and is completed.

25 ed with ClinicalTrials.gov, NCT01798680, and is completed.

26 ons not possible until future cohort studies are completed.

27 me 18 participants two years after treatment was completed.

28 il the critical portion of the first surgery was completed.

29 95% confidence interval, 51-99), 8 of which were complete.

30 cterization of the glycoproteome has not yet been completed.

31 inicalTrials.gov, number NCT02234843 and has been completed.

32 nes used during the 2017-2018 season has not been completed.

33 ClinicalTrials.gov, NCT02937454, and has now been completed.

34 t vaccines used during the 2017-2018 has not been completed.

35 artments like the intestinal mucosa, has not been completed.

36 ls of iPSC-derived cells have not previously been completed.

37 alTrials.gov, NCT02924883, and the study has been completed.

38 The trial, including all follow-up, has been completed.

39 RVX-208 (now called apabetalone) has already been completed.

40 i-decadal variability of the ISM is far from being complete.

41 s), subtypes and HIV-1 diversity estimations were completed.

42 ible PICU admissions, for whom 1,218 surveys were completed.

43 69 carotid MR imaging studies were completed.

44 Histologic analyses of lesions were completed.

45 ut the veterans health administration system were completed.

46 hundred forty-two perioperative enhancements were completed.

47 nvestigator until all other study procedures were completed.

48 ial feasibility purposes, 6-month follow-ups were completed.

49 21 August 2017) and before trial recruitment was completed (30 September 2018) when informed that pro

50 A total of 2295 of 5282 surveys were completed (43.4% response rate).

51 eration of datasets that hold the promise of being complete, accurate and permanent.

52 nodes of Ranvier and appears as myelination is completed, acting as an ion-diffusion barrier that af

53 lment, neoadjuvant therapy, and surgery have been completed; adjuvant treatment and follow-up are ong

54 cording to the ROC curve, the learning curve was completed after 25 procedures.

55 for target immobilization and the selection was completed after ten rounds.

56 Of the total, 1,243 were completed after 2007, when the mean 1-year publicat

57 t-Traumatic Stress Scale 10 intensive part B were completed after inclusion, and reevaluated after 3,

58 consensus was reached or 4 survey rounds had been completed, after which the question was categorized

59 aphic/behavioral/psychosocial questionnaires were completed, along with HIV and HCV testing.

60 s the phase 1b 25-mg lenalidomide cohort was being completed; an additional 25-mg cohort in phase 2 i

61 ly assume the collected annotations of genes are complete and only integrate multiple RNA-seq dataset

62 A prototype 3-segment imager has been completed and tested with an active 64-cm axial fie

63 number of randomized controlled trials have been completed and the first drugs, all therapeutic mono

64 The salamander skeleton is complete and articulated, suggesting it was caught an

65 The accrual is complete and final results are presented here.

66 PACE-B recruitment is complete and follow-up is ongoing.

67 The trial is complete and is registered, with EudraCT, number, 201

68 Recruitment is complete and long-term follow-up is ongoing.

69 Recruitment to all cohorts is complete and long-term follow-up is ongoing.

70 This trial is complete and registered at ISRCTN (ISRCTN30393230).

71 ormers in which the loading of Mcm2-7 on DNA is complete and the DNA entry gate is fully closed.

72 alTrials.gov, NCT02426125; patient enrolment is complete and the last patient on treatment is being f

73 nt cells from dying before viral replication is complete and the mature virus is released from the ce

74 This study is completed and was registered with the ISRCTN, number

75 cess regression was used to ensure estimates were complete and comparable across time and to generate

76 thheld until standard staging investigations were complete and the first treatment decision made.

77 reveal that of 103 pit latrines studied, 88% were completed and in use, but only 35% were operated ap

78 st year, three cardiovascular outcome trials were completed and showed that PCSK9 inhibitors signific

79 ring in reconstructing GO both when the data are complete, and incomplete.

80 cutoff, the 24-month dose-finding study had been completed, and 30 patients had been enrolled in an

81 Enrolment has been completed, and follow-up is ongoing.

82 Study recruitment is complete, and follow-up of the maintenance phase is o

83 Patient enrolment is complete, and the study is registered with ClinicalTr

84 Recruitment is complete, and the trial is in follow-up.

85 A systematic review of the literature was completed, and the Grading of Recommendations Assess

86 Transit through megakaryocytes can be completed as rapidly as minutes, after which neutroph

87 The work was completed as part of the PhysioNet 2019 Challenge al

88 Hippocampus-dependent cognitive tasks were completed as well.

89 s extract these lipids after their synthesis is completed at the inner membrane and transport them to

90 dependent and that a reaction with NO, which was complete at 8-10 NO molecules per cluster, resulted

91 A self-harm questionnaire was completed at ages 16 years and 21 years.

92 ay (MID) task during functional neuroimaging was completed at baseline and after 2 weeks of treatment

93 d P-wave duration and atrial late potentials were completed at 0, 10, and 24 months.

94 Follow-up assessments were completed at 3 months post-injury.

95 Neuromuscular assessments were completed at baseline and for 45 min post-exercise.

96 Weight measurements were completed at baseline, and then weekly for 4 weeks,

97 Organizational assessments were completed at sites once before and 4 times after im

98 ll necessary procedures and optimal settings are completed automatically by the software.

99 ADC maturation was completed between 1.3 and 2.4 years of age, dependin

100 ve observational studies of surgery patients were completed between 3/2017 and 12/2018.

101 The study is completed but survival follow-up is ongoing.

102 initiate until 30 min after application and is complete by 2 h.

103 tes a rearrangement, and the catalytic cycle is completed by reduction of the new enone.

104 tion and coupling of pairs of tyrosines, and is completed by TG proteolysis(3).

105 Further, the picture is completed by the observation that hAEC express A1, A2

106 ubic Mg(2)TiO(4) to the tetragonal structure was complete by 29.2 GPa, ~5 GPa higher than the transit

107 ted by 1,548 (96.2%), and 24 weeks follow-up was completed by 1,503 (93.4%); follow-up was similar be

108 Twelve weeks follow-up was completed by 1,548 (96.2%), and 24 weeks follow-up w

109 he Moroccan Arabic version of the LARS score was completed by 143 patients.

110 The survey was completed by 2,961 patients (mean age 65.1 years, st

111 The study was completed by 30 HV, 27 FD-starters, and 18 FD-stoppe

112 ening group who were mailed a FIT, screening was completed by 33.1%.

113 The patient survey was completed by 513 patients with mild (26%), moderate

114 efecation and Fecal Continence questionnaire was completed by a representative sample of the adult Du

115 Carba-R NxG testing was completed by Cepheid (Sunnyvale, CA), blinded to gen

116 Data extraction was completed by independent pairs of reviewers.

117 uation, and release criteria of the product, was completed by isolation facilities participating at t

118 , 2011, and November 14, 2014, and follow-up was completed by January 15, 2018.

119 rlands, and the United States, and follow-up was completed by May 2018.

120 The study was completed by the development of a highly efficient r

121 This was completed by the operational determination of the ir

122 19-100; 31 men] using the standard technique was completed by three thoracic radiologists to assess i

123 Quality appraisal was completed by two reviewers independently in duplicat

124 Baseline quality-of-life questionnaires were completed by 1438 (92%) of 1566 patients and 9-mont

125 Clinical utility surveys of MRI examinations were completed by 150 physicians.

126 Six-month assessments were completed by 258 participants (129 intervention, 12

127 Cognitive performance assessments were completed by 5,972 and 4,939 respondents at 11 year

128 Study visits were completed by 89%, 77%, and 75% of men at months 2,

129 In addition, questionnaires were completed by children, parents and dentists.

130 All assessments were completed by independent evaluators masked to treat

131 DOT or VOT observation records were completed by observers until treatment or study end

132 nd posttreatment examinations and treatments were completed by ophthalmologists with expertise in ROP

133 Subgroup analyses were completed by SCH genotype.

134 een November 2013 and July 2017; assessments were completed by the end of February 2018.

135 Data extraction and risk of bias assessment were completed by the same two reviewers.

136 e available for singleton pregnancies, there was complete concordance between all trophoblasts unless

137 ductive approach for vaccine development may be complete deletion of specific glycans in the E2 prote

138 tibody response to neutralizing epitopes may be complete deletion, rather than just modification, of

139 the time at which half of the daily activity is completed) did not vary across level of VF damage.

140 FACT-P and EQ-5D-5L were completed during cycles 1-7, then every other cycle

141 h the maximum tolerated dose of ALDC1, there was complete eradication of 83.33% of the tumors in the

142 The primary endpoint was complete fistula healing (no symptoms of discharge,

143 After osseous recontouring was completed, flaps were sutured and compressed, and bo

144 On Days 1 and 10, a sleep study was completed following exposure to MIH or the SP.

145 syn), a range of recognition studies can now be completed for producing novel supramolecular catalyst

146 Phase 3 trials have also been completed for bempedoic acid (targeting ATP-citrate

147 However, the same evidence that is complete for some individuals or groups may be incomp

148 Vital status information at 10 years was complete for 841 (93%) patients in the PCI group and

149 Follow-up was complete for more than 99% of the study participants

150 Treadmill test was completed for 128/212 (60%) patients.

151 Postoperative imaging was completed for 19 patients >1 year after surgery and

152 Follow-up at 180 days was completed for 779 patients (99.7%).

153 llow-up of 10 years until December 31, 2015, was completed for all participants.

154 Follow-up at 24 months was completed for more than 90% of the participants.

155 Imaging studies were completed for 40 patients (mean age, 40.4 years; 23

156 BPI and BFI were completed for 7 consecutive days (days -6 to 1 incl

157 Prenatal ultrasounds were completed for each twin, and histomorphologic analy

158 Separate analyses were completed for SP and LP, using 2-by-2 contingency t

159 ata from 3 studies in the United States that were completed from 2012 to 2013, 2006 to 2008, and 1959

160 (<50%) in the unspiked system, while removal was complete (>99%) in the spiked systems.

161 The entire procedure can be completed in 10 d.

162 Preparation of single-cell suspensions can be completed in 2.5 h.

163 The presented protocol can be completed in 4 d and quantifies metabolic fluxes with

164 The protocol described herein can be completed in 4 d.

165 ines have been established, the protocol can be completed in 5 d, with a throughput of hundreds to th

166 n of SWNTs to expression quantification, can be completed in 5 d.

167 sample preparation to HCP identification) to be completed in 7-8 h while demonstrating the ability to

168 The method can be completed in a few hours without the need for next-ge

169 s small enough such that the simulations can be completed in a short time frame but large enough to e

170 The same chiral analysis can now be completed in almost a third of the time with the addi

171 limit of detection of a single copy and can be completed in around 15 min.

172 Sequencing using the nanopore platform could be completed in less than an hour, and samples could be

173 0%) of Tregs, reinforcing that MSRE-qPCR can be completed in less time than other methods with the sa

174 ble more, larger trials in kidney disease to be completed in the current era of burdensome regulation

175 ventional protocol, expansion pathology, can be completed in ~1 d with immunostained tissue sections

176 Ctx-IF can be completed in ~1 week and provides an opportunity to s

177 The whole protocol can be completed in ~7 d, including ~5 d required for the de

178 Similarly, fewer clinical trials have been completed in PDAC (n = 608) compared with breast (n

179 e machine is rapid: Peptide chain elongation is complete in hours.

180 eurons with adeno-associated viruses (AAVs), is completed in a few minutes and allows stable transgen

181 Haem synthesis is completed in mitochondria, with ferrochelatase adding

182 ls, demonstrating that reverse transcription is completed in the nucleus.

183 ing nuclear import, revealing that uncoating is completed in the nucleus.

184 Clinical response was complete in 10 patients, partial in 10 patients, and

185 Recovery was complete in all patients except in those with ocular

186 Bq), labeling of (18)F-rhPSMA-5 to -10 by IE was completed in < 20 min (radiochemical yields, 58% +/-

187 Twelve-month follow-up was completed in 148 of 152 randomized subjects (97.3%).

188 Cycloplegic refraction was completed in 15 051 children 6 to 72 months of age.

189 Angiographic follow-up at 25 months was completed in 167 patients (91.8%), and the median cl

190 Serum CrAg testing was completed in 227 patients with cryptococcosis.

191 Pharmacotyping rapidly-expanded PDOs was completed in a median of 48 (range 18-102) days.

192 e clinical guidelines, this technical review was completed in accordance with the Grading of Recommen

193 from July 2017 to March 2019, and follow-up was completed in August 2019.

194 ollment began in December 2007 and follow-up was completed in February 2019.

195 The final follow-up visit was completed in January 2020.

196 een January 2016 and January 2019; follow-up was completed in June 2019.

197 Analysis was completed in line with the process set out within co

198 A literature search was completed in PubMed, PsycINFO, and Scopus.

199 solution computed tomographic (HRCT) imaging were completed in a subset of participants at age 26.

200 cokinetic and anti-drug antibody assessments were completed in participants with at least 56 days of

201 For both cohorts combined, 389 HBsAg tests were completed in the alert group compared to 177 HBsAg

202 Critical appraisal was completed independently by 2 investigators.

203 In other words, the drug-disease matrix to be completed is low-rank.

204 eparation of daughter cells once mitosis has been completed, is executed in fungal and animal cells b

205 Once the form was completed it was collected by EGPAF staff and entere

206 Follow-up was completed June 24, 2019.

207 lure to undergo apoptosis when tissue repair is complete, lead to pathological fibrosis and are also

208 ted, as cell division before DNA replication is complete leads to genome instability and cell death.

209 le research into non-miRNA sRNA function has been completed, likely due to some major barriers that p

210 ts with PDR, 2,407 (54.4%) and 2,320 (52.4%) were complete LTFU at 6 months and 1 year, respectively;

211 A retrospective analysis was completed of recipients of a living donor liver tran

212 Vast amount of research has been completed on the aroma profile of celery.

213 Follow-up was complete on October 23, 2018.

214 Thermal imaging at 8-um to 13-um wavelengths was completed on 30 test subjects with a suspected activ

215 Trial enrolment began on March 30, 2012, and was completed on April 10, 2014.

216 Final follow-up was completed on July 21, 2020.

217 and Sept 18, 2017, and the follow-up period was completed on March 1, 2018.

218 up for 1 year (follow-up of all participants was completed on March 7, 2018).

219 ventional testing began on Nov 14, 2016, and was completed on Nov 26, 2017, for tests done between Ma

220 Final 28-day follow-up visit was completed on November 28, 2018.

221 15, 2018, through March 27, 2019; follow-up was completed on November 4, 2019.

222 commenced on October 25, 2016, and follow-up was completed on October 22, 2018.

223 g a variety of NK cell activation conditions was completed on primary human NK cells and the NK92MI c

224 RAI assessments were completed on 36,261 unique patients presenting to s

225 Nutritional Status and Growth (STRONGkids)] were completed on admission.

226 SP and LP UATs were completed on all included patients.

227 Confusion Assessment Method and Sour Seven) were completed once daily.

228 its prolonged maturation time course, which is completed only by end of adolescence.

229 A number of placebo-controlled studies have been completed or are underway utilizing IL-1, IL-23, IL

230 T-cell epitopes targeted in type 1 diabetes was completed over a decade ago, providing an important

231 The primary endpoints were complete pathologic response (pCR), disease-free su

232 k-free functional magnetic resonance imaging was completed prior to randomization and 1 month followi

233 Of manually curated genomes, 22 (18 are complete), ranging from 159 kilobase (kb) to 527 kb

234 If lethality is complete, releasing this strain should only reduce po

235 The primary end point was complete remission (CR) on induction.

236 Secondary outcomes were complete resection and recurrence at first surveill

237 FLAIR abnormalities, and after 2 years there was complete resolution of abnormal multifocal reduced d

238 One month later, there was complete resolution of his symptoms and SRF.

239 The primary end point was complete response (CR).

240 The primary endpoint was complete response at any time in patients with carci

241 ad an objective response, of which four (7%) were complete responses and 27 (50%) partial reponses.

242 romotes cell cycle progression before repair is completed resulting in mitotic catastrophe.

243 Thirty-nine biopsies were completed, resulting in 12/39 (30.8%) malignancies

244 Once virus assembly is complete, retroviruses, like most enveloped viruses,

245 Our data show that after ER fusion is completed, RHD3 is degraded by LNPs so that nascent t

246 All non-N-back tasks were completed several days separate from the N-back by

247 es on Science With Treatment Recommendations were completed since 2015 are also summarized here.

248 The primary outcome was complete success at 9 months, which was defined as i

249 dverse events included 16 deaths, 4 of which were completed suicides (GSP=2; GHE=2), and 12 of which

250 ivity occurring after the resolution cascade is complete that alters the immune physiology of tissues

251 f the Grand Ethiopian Renaissance Dam (GERD) is completed, the Nile will have two of the world's larg

252 While more research needs to be completed, this study will help update cancer screeni

253 Follow-up ascertainment of cancer diagnoses was complete through September 12, 2019.

254 ew of 73 horizontal ridge augmentation cases was completed to assess the clinical outcomes, 53 of tho

255 Furthermore, a matched pair analysis was completed to determine structural changes that impac

256 profiling of 67 critically injured patients was completed to establish a metabolic signature associa

257 Statistical analysis was completed to identify whether the use of postoperati

258 TWAS (transcriptome-wide association study) was completed to integrate transcriptomic data from 233

259 groups, and cognitive debriefing interviews were completed to define content.

260 Two studies were completed to determine clinical performance.

261 After search or upload is complete, users can choose the criterion for binder v

262 first synthesis of lacto-N-hexaose (LNH) has been completed using a convergent strategy.

263 t total synthesis of halistatins 1 and 2 has been completed using Cr-mediated coupling reactions for

264 of hepatology providers in the United States was completed using primary and secondary data sources.

265 Methylation assays were completed using the Infinium HumanMethylation450 Be

266 m point of view, which we adopt here, mixing is complete when the substances come together across sma

267 tions relate to when diagnostic tests should be completed, which diagnostic tests to utilize, and the

268 The SSDT was completed while looking at a photograph of one's own

269 Recruitment is complete with a total of 19 Stage IIIC-IV OC patients

270 The primary analysis is complete with long-term follow-up ongoing.

271 This study was completed with 49 women.

272 d group overall, 66.2% of the order sessions were completed with 1 record open, including 34.5% of ED

273 Data search and extraction were completed with a standardised data form and any dis

274 riven by ballistic S-C bond extension and to be complete within 350 fs.

275 protocol comprises three phases that can all be completed within 1 d.

276 proteins of interest by western blotting can be completed within 1-2 weeks.

277 The overall analysis could be completed within 15 min.

278 whole protocol, including the analysis, can be completed within 2 weeks.

279 It can be completed within 24 weeks (using Step 5A/C) or 10 wee

280 rains have been generated, this protocol can be completed within 30 min to a few hours, depending on

281 on of microscopy data and image analysis can be completed within 5 d, requiring only standard laborat

282 matographic strip test for LMG detection can be completed within 5 min without any incubation, washin

283 The overall operation can be completed within 7 min of sample loading.

284 The procedure described in this protocol can be completed within 8 d.

285 The entire procedure can be completed within a few weeks.

286 nalysis) for both 3D and 4D-LC/MS setups can be completed within less than 1-2 days, compared to week

287 origins are indispensable for replication to be completed within S-phase period.

288 trigger a developmental pathway that cannot be completed within the growing season, referred to as a

289 ng 3D T2 mapping technique at 3.0 T that can be completed within the period of adenosine stress (<=4

290 The protocol can be completed within ~9 d for four biological replicates

291 ocess in the reduced-dimensional perovskites is complete within 1 min, whereas a similar reaction onl

292 The terpene coordination is complete within 10 min and coincides with spontaneous

293 rall the entire workflow of data acquisition is completed within a day using the multidimensional on-

294 The process is completed within seconds, holding great potential for

295 t, along with calibration and 12 replicates, was complete within 5 min, consuming under 150 nL of sol

296 Ultrasonic debridement was completed within 24 hours in FMD and FMUD groups.

297 lytes extraction from 100 mL aqueous samples was completed within 50 min and stripping in methanol re

298 lts suggest that this macroevolutionary jump was completed within a relatively short time interval (9

299 h a viscosity of ca. 21.6 cP at 40 degrees C was completed within the fluorescence lifetime, so that

300 ral proteins and the viral life cycle cannot be completed without protease activity.